AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty : The RAVEN cohort study
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved..
OBJECTIVES: Despite being prioritized during initial COVID-19 vaccine rollout, vulnerable individuals at high risk of severe COVID-19 (hospitalization, intensive care unit admission, or death) remain underrepresented in vaccine effectiveness (VE) studies. The RAVEN cohort study (NCT05047822) assessed AZD1222 (ChAdOx1 nCov-19) two-dose primary series VE in vulnerable populations.
METHODS: Using the Oxford-Royal College of General Practitioners Clinical Informatics Digital Hub, linked to secondary care, death registration, and COVID-19 datasets in England, COVID-19 outcomes in 2021 were compared in vaccinated and unvaccinated individuals matched on age, sex, region, and multimorbidity.
RESULTS: Over 4.5 million AZD1222 recipients were matched (mean follow-up ∼5 months); 68% were ≥50 years, 57% had high multimorbidity. Overall, high VE against severe COVID-19 was demonstrated, with lower VE observed in vulnerable populations. VE against hospitalization was higher in the lowest multimorbidity quartile (91.1%; 95% CI: 90.1, 92.0) than the highest quartile (80.4%; 79.7, 81.1), and among individuals ≥65 years, higher in the 'fit' (86.2%; 84.5, 87.6) than the frailest (71.8%; 69.3, 74.2). VE against hospitalization was lowest in immunosuppressed individuals (64.6%; 60.7, 68.1).
CONCLUSIONS: Based on integrated and comprehensive UK health data, overall population-level VE with AZD1222 was high. VEs were notably lower in vulnerable groups, particularly the immunosuppressed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:88 |
|---|---|
| Enthalten in: |
The Journal of infection - 88(2024), 4 vom: 15. Apr., Seite 106129 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meeraus, Wilhelmine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
B5S3K2V0G8 |
|---|
| Anmerkungen: |
Date Completed 03.04.2024 Date Revised 03.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2024.106129 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369210336 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369210336 | ||
| 003 | DE-627 | ||
| 005 | 20240403235551.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240304s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2024.106129 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1363.xml |
| 035 | |a (DE-627)NLM369210336 | ||
| 035 | |a (NLM)38431156 | ||
| 035 | |a (PII)S0163-4453(24)00063-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Meeraus, Wilhelmine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty |b The RAVEN cohort study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.04.2024 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVES: Despite being prioritized during initial COVID-19 vaccine rollout, vulnerable individuals at high risk of severe COVID-19 (hospitalization, intensive care unit admission, or death) remain underrepresented in vaccine effectiveness (VE) studies. The RAVEN cohort study (NCT05047822) assessed AZD1222 (ChAdOx1 nCov-19) two-dose primary series VE in vulnerable populations | ||
| 520 | |a METHODS: Using the Oxford-Royal College of General Practitioners Clinical Informatics Digital Hub, linked to secondary care, death registration, and COVID-19 datasets in England, COVID-19 outcomes in 2021 were compared in vaccinated and unvaccinated individuals matched on age, sex, region, and multimorbidity | ||
| 520 | |a RESULTS: Over 4.5 million AZD1222 recipients were matched (mean follow-up ∼5 months); 68% were ≥50 years, 57% had high multimorbidity. Overall, high VE against severe COVID-19 was demonstrated, with lower VE observed in vulnerable populations. VE against hospitalization was higher in the lowest multimorbidity quartile (91.1%; 95% CI: 90.1, 92.0) than the highest quartile (80.4%; 79.7, 81.1), and among individuals ≥65 years, higher in the 'fit' (86.2%; 84.5, 87.6) than the frailest (71.8%; 69.3, 74.2). VE against hospitalization was lowest in immunosuppressed individuals (64.6%; 60.7, 68.1) | ||
| 520 | |a CONCLUSIONS: Based on integrated and comprehensive UK health data, overall population-level VE with AZD1222 was high. VEs were notably lower in vulnerable groups, particularly the immunosuppressed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19 vaccines | |
| 650 | 4 | |a ChAdOx1 nCoV-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a ChAdOx1 nCoV-19 |2 NLM | |
| 650 | 7 | |a B5S3K2V0G8 |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Joy, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Ouwens, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Kathryn S |e verfasserin |4 aut | |
| 700 | 1 | |a Venkatesan, Sudhir |e verfasserin |4 aut | |
| 700 | 1 | |a Dennis, John |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Trung N |e verfasserin |4 aut | |
| 700 | 1 | |a Dashtban, Ashkan |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Xuejuan |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Morris, Tamsin |e verfasserin |4 aut | |
| 700 | 1 | |a Carty, Lucy |e verfasserin |4 aut | |
| 700 | 1 | |a Kar, Debasish |e verfasserin |4 aut | |
| 700 | 1 | |a Hoang, Uy |e verfasserin |4 aut | |
| 700 | 1 | |a Feher, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Forbes, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Jamie, Gavin |e verfasserin |4 aut | |
| 700 | 1 | |a Hinton, William |e verfasserin |4 aut | |
| 700 | 1 | |a Sanecka, Kornelia |e verfasserin |4 aut | |
| 700 | 1 | |a Byford, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Anand, Sneha N |e verfasserin |4 aut | |
| 700 | 1 | |a Hobbs, F D Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Clifton, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Pollard, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Sylvia |e verfasserin |4 aut | |
| 700 | 1 | |a de Lusignan, Simon |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 88(2024), 4 vom: 15. Apr., Seite 106129 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:88 |g year:2024 |g number:4 |g day:15 |g month:04 |g pages:106129 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2024.106129 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 88 |j 2024 |e 4 |b 15 |c 04 |h 106129 | ||